ACONW — Aclarion, Inc.

Nasdaq · Health Care · Health Care Providers & Services · CIK 1635077 ·
Last close
Market Cap
52W High
52W Low
ADV30
Next earnings
Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and imaging data transfer products, including AMBRA Healthcare, a data transfer platform. In addition, the company offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes the NOCICALC results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs examined in the patient. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 21,140 3,750 -2,986,941 -2,853,575 20,640,687 19,004,976 986,208
Dec 2025 18,479 1,791 -1,992,994 -1,889,142 13,672,404 12,015,789 837,287
Sep 2025 18,942 4,386 -1,830,964 -1,706,294 13,200,298 11,341,336 699,747
Jun 2025 19,319 5,140 -1,736,508 -1,600,757 14,754,520 12,825,657 564,422

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-7,164,204
Investing CF
$-203,902
Financing CF
$18,945,234
CapEx
$-203,902
Dividends Paid
Buybacks
$-1,213,590
EPS Diluted TTM
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-58,495,940
Inventory
Receivables
$29,680
ST Investments
EBIT TTM
$-7,233,629
Pretax Income TTM
$-7,233,629
Interest Exp TTM
$0
Analysts

Yahoo Snapshot (yfinance, live)

Total Revenue
$77,879
EBITDA
$-8,314,259
Free Cash Flow
$-4,855,890
Enterprise Value
Total Cash
$19,004,976
Total Debt
$0
Shares Out
Trailing EPS
$-6.58
Book Value
$8.04
ROE
-45.4%
ROA
-28.8%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 75,730 -7,052,391 -7,233,629 13,672,404 837,287 -7,164,204
Dec 2024 45,724 -5,513,047 -6,992,927 2,123,483 1,153,426 -5,271,609
Dec 2023 75,404 -4,877,125 -4,911,374 2,459,774 3,187,769 -3,646,947
Dec 2022 60,444 -5,562,368 -7,068,593 2,914,629 688,671 -4,949,112

Peers — same industry

TickerNameMarket CapLastDaily %
HCA HCA Healthcare, Inc. $87.05B $392.42
NTRA Natera, Inc. $28.77B $200.91
DGX QUEST DIAGNOSTICS INC $21.35B $192.88
LH LABCORP HOLDINGS INC. $21.19B $258.45
GH Guardant Health, Inc. $15.89B $119.85

News headlines (Yahoo Finance, 1h cache)

Aclarion (ACON) Upgraded to Buy: Here's Why
2026-05-19 16:00 · Yahoo
Aclarion, Inc. (ACON) Reports Q1 Loss, Misses Revenue Estimates
2026-05-13 22:10 · Yahoo
Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment
2026-05-07 10:00 · Yahoo
Aclarion Announces Inducement Grant to New Commercial Director, Western U.S.
2026-05-06 10:00 · Yahoo
Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine
2026-05-05 10:00 · Yahoo
Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical Adoption
2026-04-30 10:00 · Yahoo
Aclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued Adoption of Nociscan
2026-04-28 10:00 · Yahoo
Aclarion Announces $2.5 Million Stock Repurchase Plan
2026-04-22 12:30 · Yahoo
Aclarion Secures U.S. Patent Advancing Scalable, AI-Driven Assessment of Chronic Low Back Pain
2026-04-16 10:47 · Yahoo
Aclarion Receives Pinnacle Award for AI Innovation
2026-04-14 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.